Literature DB >> 28734940

Role of orbitofrontal sulcogyral pattern on lifetime cannabis use and depressive symptoms.

Yann Chye1, Nadia Solowij2, Eleni P Ganella3, Chao Suo1, Murat Yücel1, Albert Batalla4, Janna Cousijn5, Anna E Goudriaan6, Rocio Martin-Santos7, Sarah Whittle8, Cali F Bartholomeusz3, Valentina Lorenzetti9.   

Abstract

Orbitofrontal cortex (OFC) sulcogyral patterns are stable morphological variations established early in life. They consist of three distinct pattern types, with Type III in particular being associated with poor regulatory control (e.g., high sensation seeking and negative emotionality, low constraint), which may confer risk for earlier onset of cannabis (CB) use and greater use in later life. The OFC sulcogyral pattern may therefore be a stable trait marker in understanding individual differences in substance-use vulnerability and associated affective disturbances in users. In a large multisite cross-sectional study, we compared OFC pattern type distribution between 128 healthy controls (HC) and 146 CB users. Within users (n=140), we explored the association between OFC pattern type and CB use level, and subsequently if level of CB use informed by OFC pattern type may mediate disturbances in affective tone, as indexed by depressive symptoms. While OFC pattern distribution did not distinguish between HC and CB groups, it informed greater lifetime use within users. Specifically, CB users with pattern Type III in the right OFC tended to use more CB over their lifetime, than did CB users with pattern Type I or II. Greater lifetime CB use was subsequently associated with higher depressive symptoms, such that it mediated an indirect association between right OFC pattern Type III and higher depressive symptoms. The present study provides evidence for neurobiological differences, specifically sulcogyral pattern of the OFC, to modulate level of CB use, which may subsequently influence the expression of depressive symptoms.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cannabis; Dependence; MRI; Orbitofrontal cortex; Sulcogyral pattern

Mesh:

Year:  2017        PMID: 28734940     DOI: 10.1016/j.pnpbp.2017.07.017

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  6 in total

1.  Does regular cannabis use affect neuroanatomy? An updated systematic review and meta-analysis of structural neuroimaging studies.

Authors:  Valentina Lorenzetti; Yann Chye; Pedro Silva; Nadia Solowij; Carl A Roberts
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-31       Impact factor: 5.270

Review 2.  Associations between cannabis use, cannabis use disorder, and mood disorders: longitudinal, genetic, and neurocognitive evidence.

Authors:  Lauren Kuhns; Emese Kroon; Karis Colyer-Patel; Janna Cousijn
Journal:  Psychopharmacology (Berl)       Date:  2021-11-06       Impact factor: 4.415

3.  Orbitofrontal sulcogyral morphology is a transdiagnostic indicator of brain dysfunction.

Authors:  Marisa A Patti; Vanessa Troiani
Journal:  Neuroimage Clin       Date:  2017-12-18       Impact factor: 4.881

Review 4.  Orbitofrontal Sulcogyral Pattern as a Transdiagnostic Trait Marker of Early Neurodevelopment in the Social Brain.

Authors:  Motoaki Nakamura; Paul G Nestor; Martha E Shenton
Journal:  Clin EEG Neurosci       Date:  2020-02-06       Impact factor: 1.843

5.  Orbitofrontal sulcogyral morphology in patients with cocaine use disorder.

Authors:  Marisa A Patti; Sarah Wochele; Yirui Hu; Paul S Regier; Anna Rose Childress; Vanessa Troiani
Journal:  Psychiatry Res Neuroimaging       Date:  2020-09-02       Impact factor: 2.376

6.  Altered orbitofrontal sulcogyral patterns in gambling disorder: a multicenter study.

Authors:  Yansong Li; Zixiang Wang; Isabelle Boileau; Jean-Claude Dreher; Sofie Gelskov; Alexander Genauck; Juho Joutsa; Valtteri Kaasinen; José C Perales; Nina Romanczuk-Seiferth; Cristian M Ruiz de Lara; Hartwig R Siebner; Ruth J van Holst; Tim van Timmeren; Guillaume Sescousse
Journal:  Transl Psychiatry       Date:  2019-08-05       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.